Cited 0 times in Scipus Cited Count

Efficacy and safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with autologous bone for the treatment of long bone nonunion: A report of a prospective case series

DC Field Value Language
dc.contributor.authorChoi, W-
dc.contributor.authorKim, BS-
dc.contributor.authorCho, WT-
dc.contributor.authorLim, EJ-
dc.contributor.authorChoi, JS-
dc.contributor.authorRyu, YK-
dc.contributor.authorCho, JW-
dc.contributor.authorSakong, S-
dc.contributor.authorOh, JK-
dc.date.accessioned2024-09-10T06:21:39Z-
dc.date.available2024-09-10T06:21:39Z-
dc.date.issued2024-
dc.identifier.issn0020-1383-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32733-
dc.description.abstractIntroduction: Recombinant human Bone morphogenetic proteins have been used for the treatment of nonunions with promising results. We have been investigating both experimentally and clinically the efficacy of the rhBMP-2 with the macro / micro-porous hydroxyapatite carrier granules on the potency on the reconstruction of long bone defect. The purpose of this study was to prospectively evaluate the efficacy and safety of this specific rhBMP-2 with HA carrier granules mixed with autologous cancellous bone in patients with nonunion and bone defect resulted from the fracture related infection. Materials and Methods: This was a retrospective review of a prospective cohort at a university hospital. Patients diagnosed with nonunion under the definition of the United States Food and Drug Administration with bone defect after long bone fractures were enrolled from January 2020 to February 2021. We included patients with atrophic and oligotrophic nonunion, and hypertrophic nonunion with malalignment that needed to be corrected. The other patient group was consisted of segmental bone defect resulted from FRI. The maximum amount of rhBMP-2 allowed in this clinical study was 6 mg and was added to autologous bone at a 1:1 ratio. Autologous bone was added to the mixture if the volume of mixed graft was insufficient to fill the bone defect. Patients were followed 3, 6, and 12 months post-operatively. Each visit, a radiograph was taken for assessment. Visual analog scale (VAS), questionnaire for quality of life (SF-12 physical component summary [PCS], mental component summary [MCS]), and weight-bearing status were collected for functional outcome assessment. Drug safety was assessed by examining BMP-2 antibodies. Results: Of the 24 enrolled patients (mean age: 57 years), 15 (62.5 %), 2 (8.33 %), and 7 (29.17 %) presented atrophic nonunion, hypertrophic nonunion with deformity, and bone defect after fracture related infection, respectively. Thirteen patients had nonunion in the femur, 9 in the tibia, and 1 in the humerus and radius. The average amount of harvested autologous bone was 9.25 g and 4.96 mg of rhBMP-2. All 24 patients achieved union after 1-year follow up. The union rate was 95.83 % and 100 % at 6 and 12 months postoperatively, respectively. Preoperative SF-12 PCS (mean: 34.71) improved at 6 and 12 months postoperatively, respectively. Preoperative SF-12 MCS (mean: 42.89) improved 12 months postoperatively (49.13, p = 0.0338). Change of VAS was statistically significant 3 months postoperatively (p = 0.0012). No adverse effects or development of BMP-2 antibodies were observed. Conclusion: BMP-2 combined with autogenous bone resulted in excellent radiographical and functional outcomes in a relatively small prospective series of patients with nonunion and bone defect, without adverse effects. Further investigations are necessary to support our finding and optimize treatment strategies in nonunion patients.-
dc.language.isoen-
dc.titleEfficacy and safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with autologous bone for the treatment of long bone nonunion: A report of a prospective case series-
dc.typeArticle-
dc.identifier.pmid39003882-
dc.subject.keywordBMP-2-
dc.subject.keywordBone graft-
dc.subject.keywordBone graft substitute-
dc.subject.keywordNonunion-
dc.contributor.affiliatedAuthorCho, WT-
dc.contributor.affiliatedAuthorSakong, S-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.injury.2024.111711-
dc.citation.titleInjury-
dc.citation.volume55-
dc.citation.number10-
dc.citation.date2024-
dc.citation.startPage111711-
dc.citation.endPage111711-
dc.identifier.bibliographicCitationInjury, 55(10). : 111711-111711, 2024-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1879-0267-
dc.relation.journalidJ000201383-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Orthopedic Surgery
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse